A clinical study led by Dr. Swee Lay Thein is underway at the National Institutes of Health and is subject to oversight by the Food and Drug Administration.

The entities involved

• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
• National Institutes of Health →

  government organization in Shah Alam, Malaysia

  • PDS Biotechnology and the National Cancer Institute entered into a collaborative R&D agreement.Sun 13:48
  • The Trump administration seeks greater control over NIH grantmaking, while Susan Collins objects to the Office of Management and Budget's involvement.Sat 04:05

Related events

• NIH cuts budgets and personnel, impacting funded research leading to FDA-approved treatments.Aug 10
• NIH data informs market need for a device that requires FDA clearance to achieve Medicare coverage.Aug 18
• A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.Sep 2
• BioVie's candidate outperformed findings from an initiative led by the National Institutes of Health.Sep 15
• A product, NitroMist®, requires FDA approval for sale, and distributor access is being established for federal supply channels.Sep 22